Suchita Pakkala MD

Department of Hematology and Medical Oncology
Assistant Professor

(404) 778-1900
suchita.pakkala@emoryhealthcare.org

Academic Appointment

Assistant Professor, Department of Hematology and Medical Oncology

Education

Degrees

MD from University of Tennessee College of Medicine
M.S. from Georgetown University
BS from Rhodes College

Research

Focus

Principal investigator for a retrospective clinical study investigating the molecular characteristics of lung cancer in HIV positive patients. Co-investigator on 13 clinical trials in Aerodigestive cancers and Sarcoma
Mentor: Suresh Ramalingam, M. D., Associate Professor, Chief of Thoracic Medical Oncology, Winship Cancer Institute, Emory University Co-principal investigator for a retrospective clinical study investigating clinical characteristics of lung cancer in HIV positive patients.
Mentor: Suresh Ramalingam, M. D., Associate Professor, Chief of Thoracic Medical Oncology, Winship Cancer Institute, Emory University Co-principal investigator for a retrospective clinical study investigating clinical characteristics of lung cancer in HIV positive patients.
Mentor: Suresh Ramalingam, M. D., Associate Professor, Chief of Thoracic Medical Oncology, Winship Cancer Institute, Emory University Co-principal investigator for a retrospective clinical study investigating clinical characteristics of lung cancer in HIV positive patients.

Publications

A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
Clin Lung Cancer Volume: 23 Page(s): e400 - e404
11/01/2022 Authors: Osta BE; Carlisle J; Steuer C; Pakkala S; Leal T; Dhodapkar M; Liu Y; Chen Z; Owonikoko T; Ramalingam S
A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease.
J Clin Rheumatol Volume: 28 Page(s): 338 - 345
10/01/2022 Authors: Higgins JP; Trinh AV; Watson ML; Beardslee T; Goyal S; Kudchadkar R; Pakkala S; Waltuck J; Momary K; Byers KF
Radiotherapy with Concurrent Versus Sequential Osimertinib for Advanced Non-Small Cell Lung Cancer: a Multi-Center Toxicity Analysis
Volume: 16 Page(s): S586 - S587
03/01/2021 Authors: Qian D; Behera M; Carlisle J; Owonikoko T; Steuer C; Pakkala S; Kesarwala A; Fischer-Valuck B; Bradley J; Curran W
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
J Immunother Cancer Volume: 8
12/01/2020 Authors: Pakkala S; Higgins K; Chen Z; Sica G; Steuer C; Zhang C; Zhang G; Wang S; Hossain MS; Nazha B
Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.
Oncologist Volume: 25 Page(s): 562 - e1012
07/01/2020 Authors: Patel SP; Pakkala S; Pennell NA; Reckamp KL; Lanzalone S; Polli A; Tarazi J; Robert-Vizcarrondo F
Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis.
Oncologist Volume: 25 Page(s): e964 - e975
06/01/2020 Authors: Behera M; Steuer CE; Liu Y; Fernandez F; Fu C; Higgins KA; Gillespie TW; Pakkala S; Pillai RN; Force S
KRAS G12C mutation associated outcomes among patients with locally advanced non-small cell lung cancer.
Volume: 38
05/20/2020 Authors: Qian D; Behera M; Steuer CE; Pakkala S; Carlisle JW; Owonikoko TK; Fischer-Valuck BW; Kesarwala AH; Bradley J; Curran WJ
Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: APropensity Score-Matched Analysis of the National Cancer Database.
Clin Lung Cancer Volume: 20 Page(s): 484 - 493.e6
11/01/2019 Authors: Tian S; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP
A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).
Volume: 37
05/20/2019 Authors: Owonikoko TK; Higgins KA; Chen Z; Zhang C; Pillai RN; Steuer CE; Saba NF; Pakkala S; Shin DM; Zhang G
Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
Volume: 41 Page(s): 1490 - 1498
05/01/2019 Authors: Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R
Personalized therapy for lung cancer: striking a moving target.
JCI Insight Volume: 3
08/09/2018 Authors: Pakkala S; Ramalingam SS
Immune checkpoint inhibitors in small cell lung cancer.
J Thorac Dis Volume: 10 Page(s): S460 - S467
02/01/2018 Authors: Pakkala S; Owonikoko TK
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Cancer Volume: 124 Page(s): 271 - 277
01/15/2018 Authors: Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable, Stage III Non-Small Cell Lung Cancer: A Phase I Study
Volume: 12 Page(s): S2013 - S2014
11/01/2017 Authors: Higgins K; Pillai R; Chen Z; Zhang C; Patel P; Pakkala S; Shelton J; Force S; Fernandez F; Steuer C
Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
J Thorac Oncol Volume: 12 Page(s): 1687 - 1695
11/01/2017 Authors: Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
JAMA Oncol Volume: 3 Page(s): 1120 - 1129
08/01/2017 Authors: Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ
Optimal thoracic radiation dose in limited stage small cell lung cancer.
Volume: 35
05/20/2017 Authors: Behera M; Zhang X; Jiang R; Pillai RN; Patel PR; Pakkala S; Steuer CE; Saba NF; Owonikoko TK; Belani C
Survival outcomes in extensive stage small cell lung cancer patients treated with thoracic radiation.
Volume: 35
05/20/2017 Authors: Higgins KA; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP
Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base.
Volume: 18 Page(s): 286 - 292
05/01/2017 Authors: Steuer CE; Behera M; Liu Y; Fu C; Gillespie TW; Saba NF; Shin DM; Pillai RN; Pakkala S; Owonikoko TK
Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR)-positive, HER2-normal metastatic breast cancer (MBC)
Volume: 77
02/01/2017 Authors: Paplomata E; Gogineni K; Meisel J; Santa-Maria C; Yuan L; Kramer J; Li XB; Zelnak A; Pakkala S; Kaklamani V
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
Hematol Oncol Clin North Am Volume: 31 Page(s): 83 - 99
02/01/2017 Authors: Pakkala S; Ramalingam SS
Trends, Patterns of Treatment and Outcomes in Non-Small Cell Lung Cancer (NSCLC) as a Second Primary: A National Cancer Data Base (NCDB) Analysis
Volume: 12 Page(s): S470 - S470
01/01/2017 Authors: Behera M; Gillespie T; Liu Y; Jia Y; Higgins K; Steuer C; Saba N; Shin D; Pakkala S; Pillai R
Evaluation of Toxicity Profile of PD-1 versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
Volume: 12 Page(s): S253 - S254
01/01/2017 Authors: Pillai R; Behera M; Owonikoko T; Kamphorst A; Pakkala S; Belani C; Khuri F; Ahmed R; Ramalingam S
Non-small cell lung cancer (NSCLC) as a second primary: Analysis of the National Cancer Data Base (NCDB).
Volume: 34
05/20/2016 Authors: Behera M; Gillespie TW; Liu Y; Jia Y; Higgins KA; Steuer CE; Saba NF; Shin DM; Pakkala S; Pillai RN
Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC).
Volume: 34
05/20/2016 Authors: Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
Role of anti-EGFR monoclonal antibody in EGFR FISH positive NSCLC patients: A meta-analysis of phase III randomized controlled trials.
Volume: 34
05/20/2016 Authors: Patel N; Behera M; Pillai RN; Owonikoko TK; Pakkala S; Belani CP; Khuri FR; Ramalingam SS
Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
J Transl Med Volume: 14 Page(s): 111
05/03/2016 Authors: Owonikoko TK; Zhang G; Kim HS; Stinson RM; Bechara R; Zhang C; Chen Z; Saba NF; Pakkala S; Pillai R
Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives.
Curr Opin Oncol Volume: 28 Page(s): 150 - 158
03/01/2016 Authors: Pakkala S; Ramalingam SS
A Systematic Review of Carboplatin-Paclitaxel versus Cisplatin-Etoposide Concurrent with Thoracic Radiation for Stage III NSCLC Patients
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S212 - S212
09/01/2015 Authors: Steuer C; Behera M; Higgins KA; Saba N; Shin D; Pakkala S; Pillai R; Owonikoko TK; Curran WJ; Belani CP
Squamous Cell Carcinoma of Lung in the United States: Analysis of the National Cancer Database (NCDB)
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S367 - S367
09/01/2015 Authors: Behera M; Owonikoko TK; Liu Y; Gillespie TW; Yuan M; Pillai RN; Steuer C; Higgins KA; Pakkala S; Belani CP
Pemetrexed versus taxane-containing platinum doublet therapy for advanced non-squamous non-small cell lung cancer (NSCLC): A systematic analysis.
Volume: 33
05/20/2015 Authors: Behera M; Pillai RN; Owonikoko TK; Pakkala S; Steuer CE; Saba NF; Shin DM; Belani CP; Khuri FR; Ramalingam SS
Trimodality therapy in the treatment of stage IIIA non-small cell lung cancer (NSCLC): Analysis of the National Cancer Database.
Volume: 33
05/20/2015 Authors: Behera M; Steuer CE; Fernandez F; Liu Y; Fu C; Gillespie TW; Higgins KA; Saba NF; Pillai RN; Force S
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
N Engl J Med Volume: 371 Page(s): 2167 - 2177
12/04/2014 Authors: Solomon BJ; Mok T; Kim D-W; Wu Y-L; Nakagawa K; Mekhail T; Felip E; Cappuzzo F; Paolini J; Usari T
Investigating the Molecular Profile of Lung Adenocarcinoma: A Single-Institution Analysis
Volume: 90 Page(s): S50 - S51
11/15/2014 Authors: Steuer C; Behera M; Rossi M; Fisher K; Sica G; Gal A; Pakkala S; Pillai R; Owonikoko T; Khuri F
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
Cancer Volume: 118 Page(s): 5278 - 5282
11/01/2012 Authors: Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ
Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy.
Cancer Volume: 118 Page(s): 164 - 172
01/01/2012 Authors: Pakkala S; Chen Z; Rimland D; Owonikoko TK; Gunthel C; Brandes JR; Saba NR; Shin DM; Curran WJ; Khuri FR
Lung cancer in HIV-positive patients.
J Thorac Oncol Volume: 5 Page(s): 1864 - 1871
11/01/2010 Authors: Pakkala S; Ramalingam SS
HIV-associated lung cancer in the era of highly active antiretroviral therapy (HAART): Correlation between CD4 count and outcome.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Pakkala S; Chen Z; Rimland D; Owonikoko TK; Gunthel C; Brandes JC; Saba NF; Curran WJ; Khuri FR; Ramalingam SS
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Clin Lung Cancer Volume: 10 Suppl 1 Page(s): S17 - S23
03/01/2009 Authors: Pakkala S; Ramalingam SS
Prognostic significance of early peripheral blood blasts clearance following induction chemotherapy for adult acute myeloid leukemia.
Volume: 106 Page(s): 236B - 236B
11/16/2005 Authors: Pakkala S; Winton E; Langston A; Heffner LT; Khoury HJ